BackEvaxion Biotech A/S Overview

Evaxion Biotech A/S Accounts Payable

Latest accounts payable for EVAX: $0.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$0.00

Peer average / median

Loading

Evaxion Biotech A/S Accounts Payable History

Loading

Evaxion Biotech A/S vs. peers: Accounts Payable Comparison

Loading

Evaxion Biotech A/S Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Evaxion Biotech A/S (EVAX) FAQ

As of the most recent data (March 2026), EVAX shows a accounts payable of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EVAX's accounts payable is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Evaxion Biotech A/S is outperforming or lagging.

Tracking EVAX's accounts payable over time shows whether Evaxion Biotech A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Evaxion Biotech A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $0) with ownership activity and broader fundamentals.

Evaxion Biotech A/S's accounts payable is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.